Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 39 of 88 · 4203 articles
People with IBD may be interested because the article describes a potential new probiotic genus (Weissella) that has preclinical effects on inflammation and mucosal healing—areas relevant to managing flares and...
The review aggregates published instances where combining two advanced immunomodulators was followed by improvement in pyoderma gangrenosum, a serious skin complication often seen in people with IBD. However, the...
Based on the title and source metadata, this appears to be a video related to Inflammatory bowel disease and Procedures and surgery. The original article is from hmpgloballearningnetwork.com.
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
The study suggests that modifiable early-life factors (breastfeeding, diet, antibiotic exposure, etc.) may be linked to later IBD risk, especially Crohn's disease. That could inform future prevention research and...
Cure8 could only read part of this source from physiciansweekly.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Diet and lifestyle.
This study points to a plant-derived extract delivered in nanocarriers that reduced colon injury in a rat model of colitis, suggesting a potential route to targeted anti-inflammatory therapy that might avoid systemic...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. Open the original article for the full...
Smoking is a known risk factor for Crohn’s recurrence after bowel surgery. This study suggests newer products marketed as potentially safer (HNBT and e-cigarettes) were also linked to higher postoperative endoscopic...
People with IBD increasingly also have obesity and type 2 diabetes; this commentary suggests GLP-1 receptor agonists might affect not only metabolism but also inflammation and clinical outcomes relevant to IBD, which...
Anti‑TL1A drugs represent a new mechanism with phase 2 signals for clinical remission and endoscopic response in both UC and Crohn's disease, plus early biomarker evidence suggesting antifibrotic effects—areas directly...
Clinical trials shape available treatments and evidence; if groups of children (by race, ethnicity, or sex) are underrepresented, study results may not reflect how treatments work for them. This paper identifies...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
If you’re stable on ustekinumab for Crohn’s disease, this multicenter study found that switching to an approved biosimilar produced similar 6-month remission and safety outcomes to staying on the original product. That...
PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies...
Researchers report a modest association between higher estimated dietary sodium and greater odds of several IL-17–mediated diseases, while IBD showed a small inverse association. Patients may be interested because it...
Cure8 found this source from Journal of investigative medicine : the official publication of the American Federation for Clinical Research, but the page could not be read reliably yet. It is tagged for Inflammatory bowel...
Researchers are exploring natural compounds that might reduce intestinal inflammation and rebalance the gut microbiome. If translatable to humans, such approaches could inform new treatments or adjunctive therapies for...
Cure8 could only read part of this source from Pensoft Publishers, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Complications.
People with IBD who take long-term corticosteroids may have multiple overlapping risks for venous thromboembolism (prothrombotic effects of steroids, steroid-induced osteoporosis and fractures, and immobilization).
Cure8 could only read part of this source from Pensoft Publishers, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Complications.
The review connects UC pathological features to specific drug-delivery design needs, which could guide development of therapies that reach and act effectively in inflamed colon tissue. For people with UC, better-targeted...
IBD can cause cognitive and neurological symptoms. This preclinical study suggests a flavonoid-rich Chrysanthemum extract reduced colitis and related cognitive deficits in mice by changing the gut microbiota and...
Cure8 could only read part of this source from The American Journal of Gastroenterology, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
This study tests a common clinical question: whether increasing vedolizumab frequency helps patients who show no endoscopic response after 6 months. The results suggest intensification raised drug levels but did not...
This study will gather real‑world effectiveness and patient‑reported outcome data for guselkumab in adults with moderate‑to‑severe Crohn’s disease or ulcerative colitis, which may help clinicians and patients understand...
Patients and clinicians considering guselkumab for Crohn’s disease or ulcerative colitis may gain real-world evidence on how the drug performs across treatment lines and subgroups over up to 96 weeks. The study will...
This registry will track long-term safety and clinical outcomes in children with IBD, with a focus on infliximab (an anti‑TNF biologic) versus non‑biologic therapies. Long follow-up could help identify uncommon or late...
Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...
This trial tests a new oral live biotherapeutic designed to affect inflammation and the gut microbiome in Crohn’s disease. Early‑phase safety and pharmacodynamic results could influence future development of...
AI tools are being tailored to IBD care; this study suggests supervised fine-tuned LLMs may help with patient communication and workflow but currently lack reliable diagnostic accuracy. Patients and clinicians should...
Understanding PTMs may help researchers identify new biomarkers or therapeutic targets for ulcerative colitis, which could eventually lead to better treatments or tests. For people with UC, this explains part of why...
Perianal fistulas are a common and often challenging complication of Crohn’s disease. This surgical series provides outcome data on draining seton treatment that may help patients and clinicians understand typical...
The study identifies a plant-derived compound (curcumol) that reduced inflammation, mucosal injury, and some microbiome/metabolome disturbances in a mouse model of ulcerative colitis and links these effects to...
This study reports preclinical evidence that an herbal extract (EGST) reduced inflammation and epithelial cell ferroptosis in a mouse model of ulcerative colitis and in cell experiments, implicating the PPARγ/GPX4...
This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while...
People with IBD and their clinicians may want to be aware of possible higher rates of some non-gastrointestinal cancers (thyroid, kidney, prostate) and of factors linked to higher risk such as long-term steroid use,...
Registries that automatically extract clinical data with AI/NLP can speed research, help identify patient cohorts for studies or trials, and may eventually support better clinical decision-making for people with IBD....
The study identifies abnormal epithelial cell–death signaling that persists despite current therapies and may help explain why many people with IBD relapse. If validated, these pathways could point to new biomarkers or...
If you have overweight or obesity, this study suggests measurable blood proteins linked to inflammation may be associated with higher future risk of ulcerative colitis. Identifying such markers could help research on...
Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Complications. The original article is from Expert Review of Clinical Immunology.
Researchers are exploring new anti-inflammatory molecules for ulcerative colitis. Mechanistic data showing inhibition of macrophage M1 polarization, MAPK signaling, and antioxidant activity may help prioritize VpG for...
Butyrate supports intestinal health and is often low in IBD. A single oral compound that reliably restores luminal butyrate could — if proven safe and effective in humans — offer a new way to treat ulcerative colitis or...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Black women with Crohn’s may face higher risk of delayed diagnosis, hospitalization, surgery, and complications such as abscesses, infertility, and bone loss — issues that affect treatment choices and quality of life.
This single case shows that bedside ultrasound can detect serious abdominal problems (intussusception, ischemia) early in people with IBD even when initial vitals and labs look normal.
Chronic pain is common in people with Crohn’s disease and ulcerative colitis and can persist despite controlling gut inflammation. Brief online pain-education programs could offer a low-burden, scalable way to reduce...
New investigational therapy AZD7798 is being tested specifically for mucosal repair in people with active ileal Crohn’s disease who have an ileostomy — a group often excluded from other trials. Trial results could be...
